The PASTEUR Act, as amended, would provide $6 billion in federal funding over several years to give drugmakers incentive to develop and manufacture lifesaving medications for the small but growing number of infections highly resistant to antibiotics.
Anti-infective drug discovery startup ArrePath has launched with $20 million in seed funding to advance the development of molecules that use a dual mechanism to kill bacteria. The Princeton University spinout says its approach could overcome the drug resistance bacteria are developing to currently available products.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
It’s no news that antibiotic resistance has been a troubling situation that researchers are desperately trying to find solutions to. There have not been many new antibiotics created to fill in the gaps over the years, but it turns out some research could change the game with the help of dirt. The New York Times […]